cagrisema novo nordisk

News

Novo Nordisk shares dip further

Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.

Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday. Coming into Wednesday trading, they were down nearly 60% in the past 12 months, down 37% since the day of the CagriSema update.

Bloomberg on MSN · 1d

How Novo Nordisk Gave Up Its Weight-Loss Gains

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss. Together, these blockbuster drugs made Novo the most valuable publicly listed company in Europe. At one point, its market capitalization was even bigger than the size of Denmark’s economy.

Yahoo Finance · 1d

Novo Nordisk shares hit lowest level in over 3-years

Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.

24/7 Wall St.3d

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Should You Buy the Post-Earnings Plunge in Novo Nordisk Stock or Stay Far, Far Away?

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

11d

Novo Nordisk's Moat Is Deeper Than You Think

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down?

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

24/7 Wall St.7mon

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025)

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Nasdaq1mon

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% ... - Nasdaq

Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube ...

U.S. News & World Report1mon

Data on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild ...

(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other ...

NBC 10 Philadelphia2mon

Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing ...

Overall revenues at Novo Nordisk — which also produces diabetes and rare disease treatments — rose 18% to 78.09 billion Danish kroner versus an expected 78.18 million Danish kroner.

4don MSN

Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results